Last reviewed · How we verify
Adalimumab (ADA)
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Adalimumab (ADA) |
|---|---|
| Also known as | Adalimumab, Humira, Humira, ADA |
| Sponsor | JHSPH Center for Clinical Trials |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
By blocking TNF-α, adalimumab reduces inflammatory signaling and immune activation in conditions driven by excessive TNF-α production. This leads to decreased inflammation, reduced immune cell infiltration, and suppression of downstream inflammatory mediators. It is used across multiple autoimmune and inflammatory conditions where TNF-α plays a central pathogenic role.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Psoriasis
- Juvenile idiopathic arthritis
- Polyarticular juvenile idiopathic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Opportunistic infections
- Malignancy risk
Key clinical trials
- Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis (PHASE4)
- Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis (PHASE3)
- Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis (NA)
- Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (PHASE3)
- Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan (PHASE4)
- Baricitinib in the Treatment of Intestinal Behçet's Syndrome (PHASE2)
- Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods
- Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab (ADA) CI brief — competitive landscape report
- Adalimumab (ADA) updates RSS · CI watch RSS
- JHSPH Center for Clinical Trials portfolio CI